

# Stefano Porcelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7579712/publications.pdf>

Version: 2024-02-01

57  
papers

1,961  
citations

331538

21  
h-index

254106

43  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3151  
citing authors

#	ARTICLE	IF	CITATIONS
1	Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 183-190.	1.3	5
2	Social withdrawal and neurocognitive correlates in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2022, 37, 102-109.	0.9	3
3	The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls. <i>Comprehensive Psychiatry</i> , 2022, 117, 152335.	1.5	2
4	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and Alzheimer's disease. <i>Molecular Biology Reports</i> , 2020, 47, 191-200.	1.0	6
5	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	2.5	32
6	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 200-202.	0.7	6
7	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	1.0	9
8	Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 38-46.	2.9	19
9	The brief assessment of cognition in affective disorders: Normative data for the Italian population. <i>Journal of Affective Disorders</i> , 2019, 252, 245-252.	2.0	8
10	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019, 252, 464-474.	2.0	27
11	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 47-69.	2.9	22
12	Duloxetine plasma level and antidepressant response. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 127-132.	2.5	23
13	Social brain, social dysfunction and social withdrawal. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 10-33.	2.9	216
14	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 273-286.	1.1	5
15	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 62-74.	1.1	3
16	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017, 91, 1-13.	1.5	77
17	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , 2017, 34, 1482-1497.	1.3	3
18	Escitalopram plasma levels and antidepressant response. <i>European Neuropsychopharmacology</i> , 2017, 27, 940-944.	0.3	45

#	ARTICLE	IF	CITATIONS
19	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. <i>Neuropsychobiology</i> , 2017, 76, 209-221.	0.9	11
20	Possible biomarkers modulating haloperidol efficacy and/or tolerability. <i>Pharmacogenomics</i> , 2016, 17, 507-529.	0.6	0
21	Clinical factors related to schizophrenia relapse. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 54-69.	1.2	31
22	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. <i>Neuropsychobiology</i> , 2016, 73, 160-168.	0.9	11
23	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. <i>Neuropsychobiology</i> , 2016, 74, 1-7.	0.9	15
24	Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2016, 26, 163-185.	0.3	54
25	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. <i>Psychiatry Investigation</i> , 2016, 13, 247.	0.7	15
26	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. <i>Neuropsychobiology</i> , 2015, 72, 57-64.	0.9	12
27	CACNA1C gene and schizophrenia. <i>Psychiatric Genetics</i> , 2015, 25, 163-167.	0.6	21
28	Genetic Variability in CYP2E1 and Catalase Gene Among Currently and Formerly Alcohol-Dependent Male Subjects. <i>Alcohol and Alcoholism</i> , 2015, 50, 140-145.	0.9	28
29	Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms. <i>Neuroscience Letters</i> , 2015, 604, 86-90.	1.0	12
30	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 2517-2529.	1.8	11
31	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. <i>Psychiatry Research</i> , 2015, 226, 474-483.	1.7	54
32	Clozapine augmentation with amisulpride. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, E38-E39.	1.4	6
33	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. <i>Human Psychopharmacology</i> , 2014, 29, 388-391.	0.7	11
34	Quetiapine Extended Release. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 303-306.	0.7	4
35	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 567-577.	1.6	19
36	Effects of antipsychotic drugs on insight in schizophrenia. <i>Psychiatry Research</i> , 2014, 218, 20-24.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Modulation of a number of genes on personality traits in a sample of healthy subjects. <i>Neuroscience Letters</i> , 2014, 566, 320-325.	1.0	6
38	From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 62-75.	0.9	46
39	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 481.	0.7	13
40	Early Antipsychotic Response Predictors in Schizophrenia: A Naturalistic Study. <i>Journal of Psychology &amp; Clinical Psychiatry</i> , 2014, 1, .	0.0	0
41	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>Journal of Neural Transmission</i> , 2013, 120, 1709-1715.	1.4	30
42	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 65-74.	1.8	16
43	No Effect of Serotonergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. <i>Psychiatry Investigation</i> , 2013, 10, 180.	0.7	20
44	Antipsychotic Response in the First Week Predicts Later Efficacy. <i>Neuropsychobiology</i> , 2012, 66, 100-105.	0.9	14
45	Clozapine resistance: Augmentation strategies. <i>European Neuropsychopharmacology</i> , 2012, 22, 165-182.	0.3	121
46	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2012, 22, 239-258.	0.3	283
47	Case-control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 18-26.	1.2	8
48	Generalized tonic-clonic seizure secondary to duloxetine poisoning: A short report with favorable outcome. <i>NeuroToxicology</i> , 2012, 33, 189-190.	1.4	10
49	Influence of BDNF Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. <i>Neuropsychobiology</i> , 2012, 65, 1-11.	0.9	53
50	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 305-311.	1.8	30
51	DAO variants and schizophrenia: Influence on diagnosis and treatment outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 303-310.	1.2	4
52	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , 2011, 189, 26-32.	1.7	42
53	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1101-1115.	1.5	64
54	Pharmacogenetics of Antidepressants. <i>Frontiers in Pharmacology</i> , 2011, 2, 6.	1.6	72

#	ARTICLE	IF	CITATIONS
55	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011, 45, 309-321.	1.5	133
56	NCAM1, TACR1 and NOS Genes and Temperament: A Study on Suicide Attempters and Controls. <i>Neuropsychobiology</i> , 2011, 64, 32-37.	0.9	12
57	Pharmacogenetics of antidepressant response. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 87-113.	1.4	144